In Brief
Mammalian proteases regulate the immune response by altering the activity of cytokines and chemokines. Here, Sterkel, Lorenzini, and colleagues identify a fungal protease that promotes virulence and suppresses innate immunity to infection by mimicking the immunemodulatory activity of its mammalian counterpart.
INTRODUCTION
Pathogenic fungi have been dubbed the hidden killers due to the mounting rates of fungal infections. Immune-compromised patients such as those with AIDS, organ transplants, and cancer and chemotherapy are among those at risk of serious fungal infections. The endemic dimorphic fungi are primary pathogens that collectively account for nearly one million systemic infections annually in North America (Pfaller and Diekema, 2010) . These agents infect previously healthy individuals but can also reactivate from a latent state when immunity is impaired. Among these systemic mycoses, the proportion of immune-competent persons with symptomatic illness varies according to pathogen. At one end of the spectrum, about 50% become overtly ill after infection with Blastomyces dermatitidis (Klein et al., 1986) , whereas about 10% manifest clinically significant illness with Histoplasma capsulatum (Ward et al., 1979) . The high ratio of illness to infection and the potential severity of disease underscore the pathogenic and immune-evasive potential of dimorphic fungi and make them challenging pathogens from a clinical vantage point.
Several factors have been linked to virulence in dimorphic fungi (Rappleye and Goldman, 2008) . Some include calcium binding protein (CBP) and superoxide dismutase (SOD) in H. capsulatum, glucan synthase in Coccidioides sp., a-1,3-glucan and Drk1 (dimorphism-regulating kinase) in several members, and Blastomyces adhesin-1 (BAD-1) in B. dermatitidis. Immune dysregulation is a hallmark of infections with dimorphic fungi, but there is limited insight about how fungal factors subvert immunity. SOD protects Histoplasma from oxidative stress (Youseff et al., 2012) , and surface a-1,3-glucan shields this fungus from recognition by dectin-1 . BAD-1 has multiple functions: it mediates binding of Blastomyces to macrophages and lung tissue, modulates expression of host TNF-a and TGF-b, binds calcium and other divalent cations, and impairs T cell activation and function by engaging heparin sulfate modifications of surface CD47 (Brandhorst et al., 2013) .
Failure of vaccination at the lung mucosa reveals features of immune dysregulation induced by dimorphic fungi. An attenuated, BAD-1 deletion strain of B. dermatitidis, which protects against lethal experimental blastomycosis when given subcutaneously, fails to protect when given via the respiratory route (Wü thrich et al., 2012) . Vaccine delivery at the respiratory mucosa induces a host immune regulatory circuit, which hampers the recruitment of Ly6C hi monocytes into the lungs and undermines the priming of antigen-specific CD4 + T cells within this compartment. Ly6C hi monocytes recruited to sites of inflammation play a key role in the control of infections due to bacteria (e.g., Listeria monocytogenes), parasites (e.g., Toxoplasma gondii), and fungi (e.g., Cryptococcus neoformans, Aspergillus fumigatus, and H. capsulatum) (Serbina et al., 2003 (Serbina et al., , 2008 . Upon arrival in tissue, Ly6C hi inflammatory monocytes have the ability to differentiate into macrophage and inflammatory dendritic cells (DCs), including a subset termed TipDC (TNF-a-and iNOS-producing dendritic cells) (Serbina et al., 2003) . The potent immune modulatory effects of TNF-a and powerful killing products generated with iNOS make these cells forceful effectors against invading pathogens. Thus, a paucity of Ly6C hi monocytes at sites of inflammation during host: pathogen interactions could undermine immunity in ways beyond the failure to prime antigen-specific T cells. Ly6C hi monocytes exit the bone marrow in response to soluble C-C chemokine signals received through their G protein-coupled receptor CCR2 (Serbina et al., 2008) . The chief signals in mice are CCL2, CCL7, and CCL12. We previously reported that CCL7 was elevated in the serum of mice that received the vaccine strain of Blastomyces at the respiratory mucosa (Wü thrich et al., 2012) . However, naive CCR2 + Ly6C hi monocytes failed to migrate in response to these sera in vitro, implying that the C-C chemokine was not functional. Likewise, Ly6C hi cells from vaccinated mice migrated poorly in response to recombinant CCL7, implying desensitization of CCR2, which was supported by reduced calcium flux in response to ligand-induced triggering of CCR2 in the cells. We found evidence that vaccine induction of lung matrix metalloproteinase-2 (MMP2) and its action on CCL7 accounted for blunted recruitment of Ly6C hi cells and failed priming of CD4 T cells. MMP2 is capable of cleaving five residues from the N terminus of CCL7, which inactivates the chemokine, converts it to an antagonist on CCR2, and desensitizes the receptor (Ali et al., 2005) . We found that chemical inhibition of MMP2, vaccination of MMP2 À/À mice, and delivery of CCL7 to mice helped vaccine priming of T cells in the lungs (Wü thrich et al., 2012) . However, we could not induce levels of CD4 + T cell priming achievable by yeasts that strongly recruit Ly6C hi cells into the lungs, e.g.,
H. capsulatum. Our findings implied that Blastomyces products, in addition to host MMP2, may also blunt recruitment of Ly6C hi cells to the lungs. If so, such factors could impact the host: fungal pathogen interaction and contribute to immune dysregulation and progressive infection. Microbes produce extracellular proteases that mediate virulence (Ingmer and Brøndsted, 2009 ). Here, we investigated whether a Blastomyces serine protease blunts influx or function of leukocytes at sites of inflammation and impacts pathogenesis of disease. We asked three questions: (1) is yeast viability needed to modulate leukocyte recruitment, and, if so, what products mediate the action; (2) what role is played by the serine protease di-peptidlyl peptidase IVA (DppIVA) in modulating leukocyte influx into the lungs, inflammation, and virulence of B. dermatitidis; and (3) how might DppIVA exert its action in blunting the recruitment and function of leukocytes?
We report that B. dermatitidis releases extracellular DppIVA, which curtails the influx of Ly6C hi cells into the lungs and impairs the downstream effector functions of these and other leukocytes required for innate defense. We show that DppIVA targets and cleaves C-C chemokines and GM-CSF (granulocyte-macrophage colony-stimulating factor), which has deleterious consequences for the control of infection. Our work establishes a prominent and unappreciated role for microbial DppIVA in pathogen virulence, involving modes of action that mimic the mammalian enzyme CD26, an ectopeptidase known to modulate critical aspects of hematopoiesis. Aminopeptidases are widely conserved among pathogenic microbes, including bacteria, parasites, and fungi, and may represent a strategy by which pathogens undermine mammalian innate host defenses. Mammalian DppIV can cleave and inactivate chemokines and other cytokines responsible for the recruitment and activation of multiple leukocyte populations due to the presence of target proline or alanine residues at the penultimate position of these signals (Boonacker and Van Noorden, 2003) . We identified two DppIV homologs in the B. dermatitidis genome, DppIVA and DppIVB. The former harbors a secretion signal and is likely secreted, while the latter has a predicted transmembrane domain and is presumed to be intracellular. We tested yeast supernatant for DppIV enzymatic activity and detected activity that increased during growth in vitro ( Figure 1C ). Selective DppIV inhibitors diprotin A and sitagliptin blocked the generation of signal, indicating that the supernatant activity is due to DppIV ( Figure 1D ). Mice also express DppIV (CD26), but B. dermatitidis yeast suppress phagocyte CD26 expression, while mice exposed to WT yeast mount an antibody response to fungal DppIV in vivo (Figures S1A and S1B, available online), suggesting that the fungal product also is expressed during infection.
RESULTS

A Yeast Factor Blunts Leukocyte Recruitment
DppIVA and Fungal Virulence
We silenced expression of DppIVA and DppIVB in B. dermatitidis yeast. We generated silenced strains using a GFP-RNAi sentinel system for gene silencing (Krajaejun et al., 2007) . Briefly, a GFP + strain is transformed with a plasmid harboring inverted hairpins for RNAi silencing of both the gene target and the sentinel GFP. The resulting DppIVA RNAi strain showed reduced expression of GFP and the gene of interest; the DppIVB RNAi strain was unstable, and GFP silencing could not be maintained. We silenced DppIVA by targeting the 3 0 region and 5 0 region and confirmed that DppIVA-silenced strains had reduced DppIV enzymatic activity ( Figure 1E ). The growth rate in vitro of DppIVA RNAi strains was comparable to isogenic WT GFP + strains and GFP-RNAi strains ( Figure 1F) . In a murine model of infection, lung CFU (colony-forming unit) was reduced by two to three logs with DppIVA RNAi yeast versus WT controls ( Figure 1G ). Similar results were observed for multiple independent DppIVA tranformants silenced at the 3 0 region or 5 0 region. No perturbations in expression of DppIVB transcript were detected by RT-PCR in DppIVA RNAi strains (data not shown). Thus, silencing DppIVA at multiple regions within the gene, and in multiple independent transformants, attenuated pathogenicity. Likewise, pharmacologic inhibition of DppIV with sitagliptin or diprotin A ameliorated infection in mice that received WT yeast ( Figure 1G) . DppIVA thus appears essential for virulence in B. dermatitidis.
DppIVA and Blunted Ly6C
hi Cell Recruitment
We tested a link between B. dermatitidis DppIVA and blunted Ly6C hi cell recruitment during infection. We analyzed CFU and the influx of leukocytes to the lung over 5 days postinfection . Ly6C hi cell recruitment to the lungs was greater in mice infected with DppIVA RNAi yeast than WT yeast. These recruitment differences were evident by the second day of infection ( Figure 2C ). The numbers of inflammatory macrophages and DCs were also increased in mice infected with the DppIVA RNAi strain, even though the lung CFU was significantly lower in these mice ( Figure 2C ). Ly6C hi monocytes are recruited to sites of infection via CCR2 (Serbina et al., 2008) . To test whether DppIVA is functionally linked with Ly6C hi monocyte recruitment, we analyzed the pro- Ly6C hi monocytes are recruited to the lungs via CCR2 and its ligands, CCL2, CCL7, and CCL12. We measured these chemokines in the lung, BAL (bronchoalveolar lavage), and serum and found that they were similar in mice infected with WT versus DppIVA RNAi yeast ( Figure S1D ; data not shown). Thus, differing chemokine levels do not account for blunted cell recruitment, suggesting functional differences in chemokine action between the two groups. We tested this concept by assaying CCR2 + cell migration in response to intact versus fungal DppIVAcleaved C-C chemokines. Trimming two amino acids from N terminus of these C-C chemokines, as confirmed by mass spectrometry (MS), impaired the ability of CCR2 to induce migration of reporter cells ( Figure 2F ) and of primary Ly6C hi cells (Figure S1C) . Lung MMP2 levels were >3-fold higher in mice that received WT yeast versus DppIVA RNAi yeast (data not shown), and pharmacological inhibition of MMP2 further augmented influx of Ly6C hi cells in these mice ( Figure S1C ). Thus, our Ly6C hi results can best be explained by cleavage and inactivation of one or more chemokines by DppIVA, together with elevated MMP2 and desensitized CCR2, as described (Wü thrich et al., 2012) .
Enzymatic Action of Fungal DppIVA on GM-CSF and Downstream Effects GM-CSF promotes differentiation of Ly6C hi cells into DCs in vivo
and in vitro (Hamilton, 2008) . We found that inflammatory (Ly6C hi ) DCs and TipDCs accumulated in greater numbers in the lungs of mice infected with DppIVA RNAi yeast versus WT yeast (Figures 3A and 3B) . GM-CSF expression was similarly upregulated during infection with both strains of B. dermatitidis ( Figure 3C ). However, GM-CSF harbors a penultimate proline at the N terminus and is cleaved and inactivated by mammalian DppIV (Broxmeyer et al., 2012) . We tested whether B. dermatitidis DppIVA cleaves GM-CSF in vitro. By 6 hr of incubation, DppIVA had fully removed both N-terminal residues from GM-CSF in the presence or absence of serum ( Figure 3D ), and digestion was blocked by the DppIV inhibitor diprotin A. WT yeast cultured in serum (without mammalian cells and CD26) also cleaved GM-CSF ( Figure 3E ). Since cleaved GM-CSF has diminished action on its receptor (Broxmeyer et al., 2012) , the loss of GM-CSF action could have untoward effects in vivo due to impaired differentiation of DC or activation of other leukocytes.
We tested the link between fungal DppIVA and GM-CSF in vivo during infection. We hypothesized that DppIVA cleavage of GM-CSF in vivo would promote immune evasion by WT yeast and, conversely, that loss of DppIVA would enhance GM-CSF-mediated clearance of a DppIVA RNAi strain. If true, growth of the latter strain would be preferentially enhanced in mice lacking Results are representative of two experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S1 . this cytokine. To test this hypothesis, we neutralized GM-CSF during infection ( Figures 3F and 3G ). Lung CFU in mice infected with the DppIVA RNAi strain was sharply elevated compared to infection with WT yeast in GM-CSF-neutralized mice. In contrast, neutralization of IFN-g (not expected to be a substrate of DppIVA) had a negligible effect on infection by both yeast strains ( Figure 3G ). In a second approach, we infected GM-CSF-receptor knockout (Csf2ra À/À ) mice with WT or DppIVA RNAi yeast. The absence of GM-CSF receptor signaling in Csf2ra À/À mice significantly increased growth of the DppIVA RNAi strain by 12,098-fold, while growth of the WT strain was increased by 1,166-fold ( Figure S4A ). Figure 4A ). The DsRed signal correlates with CFU ( Figures 4A and S2A) , as reported for A. fumigatus (Jhingran et al., 2012) . During coculture in vitro with DsRed yeast, TipDCs killed better than monocytes or macrophages and required iNOS for killing ( Figures 4B and S2B ). By using uvitex to stain cell-wall chitin and detect all yeast in vivo, e.g., live and dead ( Figure 4C ), we defined the identity of leukocytes associated with yeast and the ability of different leukocytes to kill them during infection. Dead yeast were more often associated with TipDCs than with Ly6C hi monocytes or Ly6C + cell-derived macrophages in vivo ( Figure 4D ). To test the role of TipDCs as a cellular basis for the loss of immune control of the silenced yeast, we transferred Ly6C hi -derived inflammatory DCs into Ccr2 À/À mice infected with DppIVA RNAi yeast. Addition of these DCs (capable of producing iNOS and TNF-a when stimulated with yeast; Figure S2B ; data not shown) enhanced the killing of DsRed yeast in vivo and did so in a manner dependent on iNOS, but not TNF-a ( Figure 4E ). Thus, TipDCs are potent effectors in vivo, and yeast DppIVA undermines their development during infection. However, proportionately more killing of yeast is mediated by macrophages and neutrophils in vivo due to their greater absolute numbers in infected lungs, and these populations also are more active against DppIVA RNAi yeast versus WT yeast in vivo ( Figure 4F ). We studied each of these leukocyte populations further below.
DppIVA Promotes Survival of Yeast in GM-CSFActivated Macrophages
To further assess how DppIVA production by yeast provides a survival advantage to the pathogen, we cocultured bonemarrow-derived macrophages with WT or DppIVA RNAi yeast in the presence of GM-CSF. GM-CSF induced meager growth inhibition of WT yeast, but the growth of DppIVA RNAi yeast was inhibited by nearly 60% ( Figure 5A ). Moreover, blocking DppIV activity with diprotin A boosted growth inhibition of WT yeast to levels near those observed for DppIVA RNAi yeast (Fig- ure 5B). To test whether addition of DppIVA would rescue growth of DppIVA-deficient RNAi yeast, we supplemented culture media with recombinant (r) Blastomyces DppIVA. Addition of rDppIVA reversed the growth inhibitory capacity of GM-CSF-activated macrophages and improved the survival of DppIVA RNAi yeast ( Figure 5B ). GM-CSF-activated macrophages from human donors yielded similar results ( Figure S3A ). Thus, DppIVA produced by yeast counteracts the antifungal effect of GM-CSF-activated macrophages.
Our in vitro studies revealed that yeast DppIVA impedes the antifungal action of macrophages in the presence of GM-CSF. To validate that GM-CSF regulates the response of macrophages to infection in vivo, we adoptively transferred peritoneal macrophages from WT or Csf2ra À/À mice into Csf2ra À/À mice just prior to infection with the DppIVA RNAi strain. The transfer of WT macrophages into Csf2ra À/À mice sharply enhanced antifungal immunity and decreased growth of the DppIVA RNAi strain in Csf2ra À/À mice ( Figure 5C ). In contrast, transfer of Csf2ra À/À macrophages failed to curtail growth of this fungal strain. Adoptive transfer of WT macrophages to Csf2ra À/À mice helped control infection with WT yeast as well, but not to the same extent as with DppIVA RNAi yeast ( Figure S4B ). Csf2ra
mice possess increased amounts of pulmonary GM-CSF due to lack of signaling via the GM-CSF receptor (Carey and Trapnell, 2010) . Introduction of WT macrophages in these mice presumably restored GM-CSF signaling in the transferred cells. Thus, GM-CSF activation of macrophages helps control a dimorphic fungus in vivo, and GM-CSF cleavage and inactivation by DppIVA from WT yeast appears to promote fungal escape from macrophage-mediated killing and progression of disease.
Impact of DppIVA Inactivation of GM-CSF on Neutrophils
GM-CSF is a polyfunctional cytokine; it activates neutrophils and augments their antifungal action (Hamilton, 2008) . We hypothesized that fungal DppIVA cleavage of GM-CSF would curtail neutrophil activation and killing of yeast. We found that the number of neutrophils recruited to the lungs during infection was higher in response to WT versus DppIVA RNAi yeast ( Figure 6A ) and correlated with higher lung CFU by day 4 of infection, although the ratio of neutrophils to yeast was lower in WT infection ( Figure S5B ). Likewise, a much smaller proportion of the cells displayed an activated phenotype in mice infected with WT versus DppIVA RNAi yeast, as measured by surface expression of CD11b or CD11a and Ly6G ( Figures 6B and S5A ). Similarly, the two groups of mice showed corresponding differences in neutrophil ROS (reactive oxygen species) production, with less ROS production in the neutrophils from mice infected with WT yeast. We tested the roles of GM-CSF and fungal DppIVA in neutrophil-mediated killing of yeast in vitro. Addition of GM-CSF to neutrophils in vitro enhanced their killing of DppIVA silenced yeast but did not affect the killing of WT yeast ( Figure 6C) ; killing required GM-CSF receptor on the neutrophils ( Figure S4C ). Addition of fungal rDppIVA prevented the killing of DppIVAsilenced yeast by GM-CSF-treated neutrophils, lowering the level of killing (10%) to that observed for nontreated neutrophils against WT yeast ( Figure 6C) . Conversely, addition of the DppIV inhibitor, diprotin A, increased the ability of GM-CSF-treated neutrophils to kill WT yeast ( Figure 6C ). Diprotin A enhanced killing of WT yeast in a concentration-dependent manner, yielding levels of killing (25%-30%) similar to that observed by GM-CSF-treated neutrophils against the DppIVA-silenced strain. Neutrophils from human donors mirrored results with murine cells ( Figure S3B ). Of note, rDppIVA did not directly affect or reduce neutrophil killing of the silenced strain; it did so only in the presence of GM-CSF ( Figure S5B ). The addition of diprotin A reversed the ability of rDppIVA to suppress killing of silenced yeast by GM-CSF-treated neutrophils ( Figure S5B ). Neither soluble DppIVA nor diprotin A affected in vitro growth of yeast in the absence of phagocytes ( Figure S5C ). Thus, fungal DppIVA blunts priming of neutrophils by inactivating GM-CSF, promoting survival of yeast and disease progression.
In murine Aspergillosis, CCR2 + monocytes augment neutrophil killing of conidia (Espinosa et al., 2014) . We found that the blunted activation state of neutrophils in Ccr2 À/À mice lacking CCR2 + monocytes mirrored that of WT mice infected with WT yeast, in which monocyte recruitment is blunted ( Figure 6D ). Likewise, although the killing of yeast in vivo in Ccr2 À/À mice is higher in activated neutrophils than in nonactivated neutrophils, killing by the former is nevertheless sharply impaired in the absence of recruited CCR2 + monocytes ( Figure 6E ). Adoptive transfer of Ly6C hi monocytes into Ccr2 À/À mice significantly enhanced the killing of DppIVA RNAi yeast in vivo by neutrophils and neutrophil-DC hybrids, as well as by macrophages (Figure S6) . Thus, Ly6C hi monocytes not only can kill the fungal pathogen directly (Figures 4B and 4C ) and can differentiate into macrophages and DCs that are even more potent killers, but Ly6C hi monocytes also appear to provide signals to neutrophils and other phagocytes that augment their ability to kill the fungal pathogen.
DISCUSSION
The dimorphic fungi exert profound immune regulatory disturbances during the course of progressive, systemic infection, but little is known about the molecular basis of these defects. We report that fungal DppIVA subverts elements of host innate immunity in a murine model of pulmonary infection with B. dermatitidis and accounts for progressive, lethal infection. Conversely, elimination of expression of DppIVA in the pathogen attenuates its virulence and is associated with restoration of early leukocyte recruitment, function, and control of disease. Thus, DppIVA is strongly implicated in these events. Gene silencing may have off-target effects, limiting the strength of our conclusions. To guard against confounding effects, we took several measures. First, we silenced multiple regions of DppIVA, including at the 3 0 and 5 0 ends. Second, we avoided targeting regions of homology with DppIVB. Third, we ensured that DppIVB transcript was unaffected in DppIVAsilenced strains and that enzyme activity was specifically reduced in DppIVA-silenced strains. Fourth, to control for random integration of silencing constructs, we studied multiple independent transformants of DppIVA-silenced strains. Fifth, we controlled for the effects of RNAi-silencing machinery by including strains in which only GFP was silenced (i.e., transformants where the transforming DNA had only GFP in the RNAi cassette) and showed that these strains have WT levels of DppIV activity and virulence. Nevertheless, we were unable to obtain a clean, targeted deletion of the DppIVA gene in B. dermatitidis, offering unambiguous proof. Still, the immune disturbances identified in our study are highly reminiscent of the actions ascribed to mammalian DppIV.
DppIV is a multifunctional protein conserved in mammals and microbes. DppIV is a member of the prolyl oligopeptidase family known for its function as a serine protease, selectively cleaving the N-terminal penultimate proline or alanine from proteins.
The best-studied DppIV is human CD26, which removes dipeptides from chemokines, binds extracellular matrix constituents such as collagen and fibronectin, and interacts with other proteins, such as adenine deaminase on T cells and a Na + /H + antiporter pump on kidney cells (Boonacker and Van Noorden, 2003) . Human DppIV cleaves CXCL10 (IP-10) and CXCL12, inactivating these attractants of T cells and hematopoietic stem cells, respectively (Ou et al., 2013) . Over 40 cytokines and chemokines display a penultimate proline or alanine and are potentially cleavable by DppIV (Ou et al., 2013) . Cleavage of such targets by microbial DppIV could foster immune evasion, but to our knowledge, there are no firm examples of this microbial evasion strategy.
We found that recruitment of Ly6C hi CCR2 + monocytes into the lungs was blunted during infection with WT yeast, but not DppIVA-silenced yeast. The C-C chemokine signals that attract these cells to sites of inflammation include CCL2, CCL7, and CCL12. The lung and serum levels of transcript and protein for these products did not differ in mice infected with these strains, implying a difference in their functional activity in the two settings. Each of these targets displays a penultimate proline target of DppIV cleavage. Removal of several N-terminal residues impairs the activity of these chemokines on CCR2, converts them into antagonists, and desensitizes CCR2 itself.
Pathogenic yeasts may prevent monocyte recruitment through mechanisms other than DppIVA cleavage of CCR2 ligands. DppIVA may indirectly upregulate MMP-2, which can block Ly6C hi monocyte recruitment by cleaving CCL7 (Wü thrich et al., 2012) . DppIV can act on M6P/IGF-IIR to induce ROS production from epithelial cells (Ishibashi et al., 2013) , and ROS can induce MMP-2 and MMP-9 production (Rajagopalan et al., 1996) . We observed a 3-to 4-fold increase in lung MMP-2 transcript and product in mice infected with WT yeast versus DppIVA RNAi yeast. Elevation in lung MMP2 likely contributes to impaired CCL7 function, as we observed with vaccine strain delivery at the respiratory mucosa (Wü thrich et al., 2012) . Fungal DppIV might also impair the migration of leukocytes during WT infection due to an impaired chemokine gradient. Mammalian DppIV binds fibronectin and collagen and promotes MMP-mediated digestion of extracellular matrix (ECM) (Boonacker and Van Noorden, 2003) . Chemokines presented on ECM establish a gradient that facilitates leukocyte migration. DppIV-enhanced destruction of ECM may therefore alter this gradient and impair the normal physiology of leukocyte migration.
One of the most profound effects of fungal DppIVA is its action on mammalian GM-CSF. This cytokine has many functions during the generation of an immune response to pathogens, involving the differentiation and activation of monocytes, macrophages, DCs, and neutrophils (Hamilton, 2008) . GM-CSF cleavage by mammalian DppIV inactivates the cytokine, and the cleaved form acts as a high-affinity, competitive inhibitor of intact GM-CSF on its receptor (Broxmeyer et al., 2012) . We found that fungal DppIVA likewise cleaves GM-CSF. During in vitro experiments, the expression of DppIVA by yeast protected the pathogen from leukocyte killing by undermining GM-CSF activation of both murine and human macrophages and neutrophils. Likewise, we detected a relative paucity of TipDCs during infection with WT yeast and found that these immune cells, when provided GM-CSF during their development, effectively kill the fungus. GM-CSF's role in defense against pathogens is complex, and its inactivation may have additional effects beyond what we describe here, including DC and macrophage differentiation, leukocyte adhesion, and cytokine production (Hamilton, 2008) .
We engineered DsRed reporter yeast to monitor host: pathogen encounters in vivo in the lung during infection. Although TipDCs were potent at killing yeast in vitro and in vivo, these immune cells accounted for only a small fraction of dead yeast in the lung compared to macrophages and especially neutrophils. Neutrophils are a signature feature of the granulomatous inflammatory response to Blastomyces, accounting for the characteristic pyogranuloma. Although these cells were most often associated with dead yeast, presumably due to their effector function, there was a striking difference in neutrophil killing of the two fungal strains in vivo, with many more viable WT yeast than DppIVA-silenced yeast. We linked this difference to impaired activation and ROS production by neutrophils in vivo. Since treatment of neutrophils with GM-CSF primes and activates them and enhances their ROS production, it is likely that inactivation of GM-CSF by DppIVA contributes to the defect. However, the blunted influx of CCR2 + monocytes that we observed-in the setting of DppIVA production or in Ccr2 À/À mice-also impaired the activation of neutrophils and their in vivo killing of the fungal pathogen. During murine pulmonary Aspergillosis, CCR2 + monocytes and monocyte-derived TipDCs promote neutrophil killing of Aspergillus conidia through a mechanism of crosstalk that augments fungicidal action of neutrophils (Espinosa et al., 2014) . Although neutrophils pour into the lesions of Blastomyces pneumonia, the cells appear to be deprived of the activation signals-GM-CSF and possibly other monocyte-derived signalsneeded to eliminate the fungus. Thus, yeast DppIVA acts in at least two ways to foster fungal survival in vivo in the face of neutrophils, by inactivating GM-CSF and impairing recruitment of CCR2 + monocytes and their communication with neutrophils.
At least 94 chemokines, cytokines, and immune-modulatory factors are potential targets for DppIV (Ou et al., 2013) . Thus, fungal DppIVA cleavage and inactivation of GM-CSF may only be part of its function. Our study focused on pathogen evasion of innate immunity. However, DppIVA may also undermine adaptive immunity. GM-CSF regulates differentiation of DCs, which bridge innate and adaptive immunity. We previously reported impaired adaptive immunity in response to fungal vaccination in the lung and attributed this defect to exuberant MMP2 and blunted recruitment of inflammatory monocytes (Wü thrich et al., 2012) . The combined effect of DppIVA and MMP2 on blunting the number and function of monocyte-derived DCs could together undermine priming of antigen-specific T cells. DppIV could also modulate adaptive immunity by cleaving and inactivating T cell-activating cytokines such as TGF-b, IL-17, and IL-23 or products such as IL-2 (Ou et al., 2013) . The many potential DppIV targets and effects their cleavage may have on the immune response to infection indicate multiple ways in which the fungus may dysregulate immunity.
The discovery of fungal DppIVA as a virulence factor makes it a potential therapeutic drug target. The DppIV inhibitor sitagliptin inhibited fungal DppIV activity in vitro, and drug treatment ameliorated disease in vivo. Sitagliptin is one of several DppIV inhibitors and was initially approved for human use to treat type 2 diabetes in 2006 (Yazbeck et al., 2009 ). DppIV inhibitors have been investigated for their ability to treat multiple diseases, including arthritis, multiple sclerosis, and inflammatory bowel disease (Yazbeck et al., 2009) . Perhaps inhibitors of DppIV could be repurposed as therapeutic adjuncts for fungal or other infections in which DppIV is found to promote microbial pathogenicity.
DppIV is conserved in mammals and microbes. We compared mammalian and fungal DppIV and found that the amino acid sequences and 3D structures are similar to one another, especially around the active site for catalytic cleavage (Figures 7 and S7) . Both of the enzymes likewise cleave at least one substrate similarly, GM-CSF. Many of the separate protease families may have evolved by convergence, but for individual subgroups, including some dipeptidyl peptidases, the genes across phyla seem to have evolved from a common ancestor (Qi et al., 2003) . To our knowledge, DppIV has not been described as a fungal virulence factor. DppIV is expressed in Aspergillus but has not been studied for a role in pathogenesis. CCL2 and CCR2 + cells promote resistance to this pathogen (Espinosa et al., 2014; Morrison et al., 2003) , reminiscent of their roles with Blastomyces. In H. capsulatum, gene deletion of DppIVA did not cause a virulence defect ). However, DppIVB is responsible for most of the extracellular DppIV activity and has not been tested for a role in pathogenicity in vivo . DppIV has been implicated in the pathogenesis of other infectious diseases such as periodontal disease from Porphyromonas gingivalis, Streptococcal toxic shock, and liver disease from Hepatitis C (Casrouge et al., 2011; Ge et al., 2009; Kumagai et al., 2000) . Similar peptidases have been studied for their role in Giardia encystation, Trypanosome pathogenesis, and malarial release from RBCs (red blood cells) (Antoine-Moussiaux et al., 2009; ArastuKapur et al., 2008; Touz et al., 2002) . The immune disturbances and progressive disease attributed here to apparent fungal mimicry of mammalian DppIV, in conjunction with the conservation of this ectopeptidase throughout the microbial kingdom, suggest an unappreciated mode of molecular piracy among microbial pathogens.
EXPERIMENTAL PROCEDURES
All work with human cells and animals was approved and conducted according to our institutional IRB and IACUC, respectively. Mice C57BL/6 WT mice were obtained from NCI (National Cancer Institute) or Jackson Laboratory. Ccr2 À/À mice were obtained from Jackson and bred in house.
Csf2ra
À/À mice were provided by Bruce Trapnell, University of Cincinnati. 
GFP-Sentinel-Silenced Strains
DppIV-silenced (RNAi) and control strains were engineered with the B. dermatitidis GFP-sentinel system (Krajaejun et al., 2007) . Two nonoverlapping sequences of DppIV at the 5 0 region and 3 0 region (BROAD: BDFG_ 07406)
were targeted for silencing. See Supplemental Experimental Procedures for detail. Vectors for silencing DppIV or GFP were transformed into Agrobacterium tumefaciens. A. tumefaciens-mediated transformation (AMT) (Sullivan et al., 2002) was used to transform the 26199-GFP strain with nonsilencing or silencing plasmids to generate a nonsilencing control strain and DppIVsilenced strains, respectively. Silenced transformants were identified by loss of GFP fluorescence and confirmed by DppIV-Glo Protease Assay (Promega).
DsRed Strains
Agrobacterium binary vector construction is described in Supplemental Experimental Procedures. Agrobacterium transformation of B. dermatitidis strain 26199 with pCAMDsRed#2 and selection for hygromycin resistance were done as described (Sullivan et al., 2002) . Transformants were screened for DsRed expression with a BioRad Versadoc 5000 (Green LED, 605 nm filter).
Red fluorescent colonies were streaked on selection medium, and isolated colonies were screened by Versadoc and analyzed by fluorescent microscopy and flow cytometry to confirm uniformly fluorescent cells.
Infection
Mice were anesthetized with isoflurane, suspended by their front incisors from a wire, and infected by intubation using a BioLite instrument (Braintree Scientific). Yeasts were given intratracheally (i.t.) by cannula. Some mice were infected i.t. by surgery. Infections were done with 2-3 3 10 4 yeast in 20 ml of PBS per mouse unless noted. Higher inocula were used to assay yeast association with small leukocyte populations or populations with low association with yeast in the lung.
Macrophages
Marrow was collected from femurs and tibias by rinsing and disruption via a 26G needle and filtered via a 40 mM filter. Macrophages were differentiated as in Supplemental Experimental Procedures and cocultured with yeast at a multiplicity of 1:1. At 24 hr postinfection, macrophages were lysed in hypotonic buffer (20 mM Tris HCl, 10 mM NaCl, 3 mM MgCl 2 [pH 7.5]), and yeasts plated on HMM agar.
Neutrophils
Neutrophils were purified from bone marrow of 6-to 8-week-old WT mice. Wells contained ratios of neutrophils to yeast of 50 to 100: 1. Some wells received 10 ng/mL GM-CSF. Cocultures were incubated for 6 hr at 37 C and 5% CO 2 . Each condition had 6-8 replicates. After cell lysis, yeasts were plated on HMM. Percent killing was defined as (1 À [# of yeast in a condition/# of yeast without neutrophils]) 3 100. Neutrophils were depleted with 250 mg a-Ly6g (clone 1A8) (BioXCell) given i.v. (intravenously) every other day.
Ly6C hi Cells
Ly6C hi cells were purified from bone marrow using a two-step approach on the AutoMACS system (Miltenyi) described in Supplemental Experimental Procedures. Ly6C-derived cells were confirmed by flow cytometry. TipDCs generated from Ly6C hi -derived inflammatory DCs produced nitric oxide and TNF-a in response to exposure to yeast ( Figure S2B ; data not shown), as measured by Griess reaction and/or respective transcript, consistent with TipDCs (Serbina et al., 2003) . To test yeast killing in vitro by Ly6C-derived cells, cells were cultured with yeast for 24 hr at 37 C (without GM-CSF) at a ratio of 3:1. For adoptive transfer into Ccr2 À/À mice, Ly6C + -derived cells were transferred as noted in Supplemental Experimental Procedures.
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